KPTI stock forecast, quote, news & analysis
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases... Show more
Why Karyopharm Therapeutics (KPTI) Stock Is Down -88% in the Last 30 Days
Key Takeaways
- Karyopharm Therapeutics (KPTI) shares fell roughly 88% over the past 30 days, sliding from about $0.80 in early October to near $0.10 following a bankruptcy filing.
- The decline accelerated after the company missed a $15.8 million debt payment in September and entered forbearance agreements with its lenders.
- On November 2, 2026, Karyopharm filed for Chapter 11 bankruptcy protection and announced a proposed merger with Ayrmid Ltd., its stalking horse bidder.
- Under the prepackaged restructuring plan, existing common stock is expected to be cancelled with no distribution to current shareholders.
- Over the last quarter the stock has fallen more than 90%, pressured by a deepening liquidity crisis and a going-concern warning.
- Analysts have downgraded the stock and withdrawn price targets, with Rodman & Renshaw moving its rating from Buy to Neutral.
- Explore additional context on Karyopharm's Price Targets, Earnings, and Forecast pages.
- Discover automated, data-driven strategies with Trending AI Robots.
Karyopharm Therapeutics (KPTI) Company Overview and Market Position
Karyopharm Therapeutics is a commercial-stage biopharmaceutical company headquartered in Newton, Massachusetts, and a pioneer in the science of nuclear export inhibition. Its lead therapy, XPOVIO (selinexor), is a first-in-class inhibitor of exportin 1 (XPO1) approved in the U.S. for adults with relapsed or refractory multiple myeloma, and marketed as XPOVIO or NEXPOVIO in more than 50 ex-U.S. countries and territories through partners. Karyopharm is advancing selinexor in myelofibrosis and exploring next-generation XPO1 inhibitors such as eltanexor. Investors have historically followed the stock for its oncology pipeline and commercial execution, but in 2026 the company's heavy debt load and tightening liquidity have come to dominate the investment narrative.
Karyopharm Therapeutics (KPTI) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, KPTI has fallen roughly 88%, dropping from an adjusted close near $0.80 in early October to under $0.10. The sharpest move came on November 2, 2026, when shares plunged more than 80% in a single session following the company's Chapter 11 filing.
The quarterly trend has been even more severe. Since early August, when the stock traded near $2.00, KPTI has declined approximately 95%, as investors progressively priced in the risk of default, restructuring, and the potential cancellation of existing equity. The move has been a sustained downward trend punctuated by brief volatility around forbearance deadlines and restructuring announcements rather than a single isolated event.
What Drove KPTI Stock Price in the Last 30 Days
The dominant catalyst was Karyopharm's slide into formal restructuring. After missing a roughly $15.8 million principal payment due September 10, 2026, the company entered forbearance agreements with its lenders and issued $20 million of convertible preferred stock as consideration, adding significant dilution risk. Forbearance was later extended to November 1, 2026, keeping the market focused on a binary outcome.
On November 2, 2026, Karyopharm and its subsidiary filed voluntary Chapter 11 petitions in the U.S. Bankruptcy Court for the Southern District of Texas and announced a proposed merger with Ayrmid Ltd., which would serve as the stalking horse bidder. Because the prepackaged plan contemplates cancelling existing common stock with no distribution to shareholders, the equity repriced sharply lower. Separately, Rodman & Renshaw downgraded the stock to Neutral and withdrew its price target, citing uncertainty over recovery value for existing shareholders. A positive pipeline milestone — the FDA's review of the supplemental New Drug Application for selinexor in myelofibrosis concluding on October 27 without a Refuse to File notice — was overshadowed by the balance-sheet events.
What Drove KPTI Stock Performance Over the Last Quarter
The quarterly decline reflects a months-long liquidity crisis. Karyopharm disclosed a going-concern warning in mid-2026, and its obligations included roughly $129 million under a credit agreement, $15.6 million of 2028 notes, $108 million of 2029 notes, and $113.5 million in revenue interest financing. With cash near $65 million and limited near-term funding, the company repeatedly warned that it might be unable to continue as a going concern absent additional capital or a strategic transaction.
Revenue trends added pressure: second-quarter 2026 revenue of about $33.4 million declined 12% year over year, partly reflecting the end of certain partnership payments, even as U.S. XPOVIO sales grew modestly. The combination of default risk, heavy dilution, and uncertain equity recovery drove the stock steadily lower across the quarter.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of automated trading strategies. Tickeron offers hundreds of AI trading bots that monitor thousands of tickers, but only top-performing and most relevant bots are featured in this section. The bots vary widely in strategy, timeframe, and performance metrics, giving users a way to compare approaches across different market conditions. For traders looking to complement their own research with systematic, data-driven signals, exploring the currently featured bots can be a useful starting point.
KPTI Stock Forecast Drivers: What Investors Should Watch Next
The near-term outlook is now tied to the bankruptcy process rather than operating fundamentals. Investors should monitor the court-supervised bidding and marketing process, including whether competing bids emerge for Karyopharm's assets, and the progress of the prepackaged plan toward its targeted confirmation hearing. A key question is whether any recovery ultimately flows to existing common shareholders, which the current plan does not contemplate.
On the pipeline side, the selinexor and ruxolitinib combination in myelofibrosis remains a clinical asset to watch as the sNDA moves through regulatory review. Additional factors include quarterly results, operating liquidity during the Chapter 11 process, and the terms of the debtor-in-possession financing. These developments carry substantial uncertainty, and outcomes depend on court approvals and restructuring negotiations that remain subject to change.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
KPTI in +83.29% Uptrend, growing for three consecutive days on October 29, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where KPTI advanced for three days, in 222 of 258 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on KPTI as a result. In 85 of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
The Moving Average Convergence Divergence Histogram (MACD) for KPTI turned negative on November 09, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 44 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KPTI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
KPTI broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for KPTI entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 5 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 43 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.004) is normal, around the industry mean (3.498). P/E Ratio (-0.004) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.226) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 99 (best 1 - 100 worst), indicating slightly worse than average price growth. KPTI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KPTI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of novel drugs for the treatment of cancer, inflammation and other diseases related to cell proliferation
Industry Biotechnology